Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib and Cetuximab in Quadruple Wild-Type Metastatic Colorectal Cancer
NCT01960023Phase 2Withdrawn
- Sponsor
- NSABP Foundation
- Start
- Oct 2013
- Primary completion
- Jul 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of neratinib in colorectal cancer (metastatic) (mCRC), sponsored by NSABP Foundation. Planned start Oct 2013; status: withdrawn.
02
Drugs
neratinib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01960023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01960023.